A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Large B-cell Lymphoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Guangxi Medical University Cancer Hospital&Guangxi Cancer Institute, Nanning, China
Contact: Study coordinator (Cen Hong)
Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital, Zhengzhou, China
Contact: Study coordinator (Keshu Zhou)

Study leads

Keshu Zhou, MD
Principal Investigator
Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes

Diffuse Large B-Cell Lymphoma (DLBCL)

Abroad (travel likely)RecruitingPHASE2

Nanjing, China

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

Diffuse Large B-cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Richmond, United States

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Sacramento, United States

Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission

Diffuse Large B-Cell Lymphoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China